Femasys (NASDAQ:FEMY) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Femasys (NASDAQ:FEMY) in a research note published on Thursday, Benzinga reports. They currently have a $12.00 price target on the stock.

Separately, Chardan Capital lowered their price target on shares of Femasys from $12.00 to $10.00 and set a buy rating for the company in a report on Wednesday, August 14th.

Femasys Stock Performance

NASDAQ:FEMY opened at $1.12 on Thursday. The firm’s fifty day simple moving average is $1.09 and its 200 day simple moving average is $1.30. The company has a current ratio of 6.47, a quick ratio of 5.93 and a debt-to-equity ratio of 0.43. Femasys has a twelve month low of $0.25 and a twelve month high of $4.75. The firm has a market capitalization of $24.89 million, a price-to-earnings ratio of -1.33 and a beta of -2.81.

Femasys (NASDAQ:FEMY) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Femasys had a negative net margin of 1,757.16% and a negative return on equity of 119.97%. The company had revenue of $0.22 million during the quarter, compared to analysts’ expectations of $0.50 million. As a group, equities research analysts expect that Femasys will post -0.79 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Femasys

A hedge fund recently raised its stake in Femasys stock. CM Management LLC lifted its stake in shares of Femasys Inc. (NASDAQ:FEMY) by 6.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 425,000 shares of the company’s stock after buying an additional 25,000 shares during the quarter. CM Management LLC owned approximately 1.91% of Femasys worth $484,000 as of its most recent filing with the Securities and Exchange Commission. 65.27% of the stock is owned by institutional investors.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.